Medtronic plc (MDT) Gains Momentum Through Diabetes and Cardiovascular Operations

Core Insights - Medtronic plc (NYSE:MDT) is recognized as one of the top 10 healthcare equipment stocks favored by hedge funds [1] - The company operates in four segments: Cardiovascular, Diabetes, Medical-Surgical, and Neuroscience, addressing over 70 chronic diseases [3] Analyst Ratings and Price Targets - Truist analyst Richard Newitter reduced the price target for Medtronic from $107 to $103 while maintaining a Hold rating, citing modest organic revenue and a slight EPS beat [1] - Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $116 to $118, indicating a potential upside of nearly 22% [2] Performance Highlights - Medtronic reported solid performance, exceeding street expectations in three out of four segments, with notable strength in the Diabetes and Cardiovascular divisions [1] - The stock's reaction to the earnings beat was moderated by preliminary commentary on potential challenges for fiscal 2027 [2]